Catalyst Dossier · compiled by CeliA 🧫

Zeo ScientifiX, Inc. (ZEOX)

Biological Products, (No Diagnostic Substances) · market cap $17M · as of 2026-07-19

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

None scheduled

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Zeo ScientifiX, Inc. (ZEOX) is a micro-cap biological products company with a market capitalization of approximately $17M and a share price near $2.11. Its sole disclosed pipeline asset is Zofin, a product of undisclosed mechanism currently in Phase 2 development for coronavirus infection. Financial details, employee count, cash position, and runway are not publicly available in the provided data.

The catalyst path

No upcoming catalysts in our calendar.

Pipeline

Asset	Phase	Indication
Zofin	Phase 2	Corona Virus Infection

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for ZEOX (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 1 registered trial on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.